Recent Pfizer Press Releases

  • 5/24/07 4:00 am EDT

    Smoking Causes 15% of EU Deaths
    Daily cost of Cardiovascular Diseases estimated 463 Million
    May 31st World No Tobacco Day

    BRUSSELS, Belgium--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) (LSE:PFZ) welcomes the European Commission’s Green Paper on smoke free environments1, which was put for public consultation earlier this year. Today in Brussels, a week before World No Tobacco Day (May 31st), the world’s leading life sciences company submitted its recommendations on the questions raised in the Commission’s Paper. The Consultation will conclude on June 1stmore...
  • 5/20/07 9:25 pm EDT

    Company to Focus on Accelerating Development and Commercialization
    of Strong Early- and Mid-Stage Pipeline

    Pfizer Also Announces Resignation of Chief Financial Officer
    Alan Levin, Who Will Continue as CFO Until Successor is Named

    NEW YORK--(BUSINESS WIRE)--Pfizer said today that the President of Pfizer Global Research and Development, Dr. John LaMattina, who made many important contributions to the Company’s research division throughout his 30-year career, will retire from Pfizer by the end of this year. The company will begin a search both inside and outside the company for his successor, and Dr. LaMattina has agreed to remain during this period to ensure a smoothmore...
  • 5/15/07 7:06 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer said its subsidiary, Pharmacia and Upjohn, will appeal today’s jury verdict linking its product, Provera, with plaintiff Merle Simon’s breast cancer. The case, Simon vs. Wyeth, et al., was heard in the Philadelphia Court of Common Pleas. “While we have great sympathy for what Mrs. Simon and her family have been through, today’s verdict is neither supported by the evidence introducedmore...
  • 5/14/07 6:27 am EDT
    BRUSSELS, Belgium--(BUSINESS WIRE)--Pfizer welcomes the 1st European Parliamentary symposium on pharmaceuticals “Putting an end to drug counter-feiting”, which convened European policy makers, regulators and specialists on counterfeiting and medicines trading in the European Parliament today. “Pfizer is very concerned about the surges in counterfeit medicines, putting at risk the lives and wellbeing of patients inmore...
  • 5/2/07 9:35 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer announced today that it has launched an online site to provide up-to-date, user-friendly information on the status of its U.S. post-marketing commitments. Post-marketing commitments are studies conducted after a medicine receives regulatory approval, often as a requirement for approval or continued marketing of some medicines. The studies are designed to provide additional information about the medicine’s safetymore...
  • 5/1/07 4:15 pm EDT

    Lyrica is First Treatment Under FDA Review for Fibromyalgia, Which Affects More than Six Million Americans

    BOSTON--(BUSINESS WIRE)--Significantly more patients treated with Pfizer’s Lyrica reduced their pain by 50 percent or more compared with placebo, according to study results presented today at the American Academy of Neurology annual meeting. Clinically, this outcome would equate to a patient with severe pain reporting a reduction to mild to moderate pain. Fibromyalgia is one of the most common chronic, widespread pain conditions and ismore...
  • 4/30/07 4:24 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc reported today that the Federal Court of Appeal of Canada has reversed a lower court ruling that would have permitted generic manufacturer Novopharm to launch a competitor product to Celebrex. The appellate court issued an order prohibiting regulatory approval of Novopharm’s product in Canada until Celebrex’s compound patent expires in November 2014. “Today’s ruling is anmore...
  • 4/30/07 6:00 am EDT

    Academy for Educational Development and Johns Hopkins are Partnering with Pfizer to Evaluate the ConnectHIV Initiative

    NEW YORK--(BUSINESS WIRE)--The Pfizer Foundation today announced the names of 20 U.S. community-based AIDS service organizations (ASOs) chosen to participate in ConnectHIV, the Foundation’s latest initiative to support organizations working to stop the spread and impact of HIV/AIDS. ConnectHIV integrates lessons learned from the Southern HIV/AIDS Prevention Initiative, the Foundation’s recently completed 3-year prevention initiative tomore...
  • 4/27/07 12:32 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Vice Chairman David Shedlarz at the 32nd Annual Deutsche Bank Health Care Conference on Wednesday, May 2, at 11:15 a.m. Eastern Daylight Savings Time, and to listen to a webcast of participation by Vice Chairman David Shedlarz and other Pfizer executives in a discussion at the Morgan Stanley Global Healthcare Unpluggedmore...
  • 4/26/07 11:00 am EDT
    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 29-cent second-quarter, 2007, dividend on the company's common stock, payable June 5, 2007, to shareholders of record on May 11, 2007. Pfizer increased its quarterly dividend to 29 cents in the first quarter of 2007 as part of a series of actions the company is taking to enhance shareholder value. The second-quarter 2007 cash dividend will be the 274thmore...